# Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia

> **NCT07373847** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Xiangya Hospital of Central South University** · enrollment: 40 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** vunakizumab and recaticimab.
- **DRUG:** vunakizumab and placebo

## Key facts

- **NCT ID:** NCT07373847
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07373847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07373847, "Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07373847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*